Stockscreener 앱 받기
1.94
3.96%
-0.08
시간 외 거래:
1.98
0.04
+2.06%
전일 마감가:
$2.02
열려 있는:
$2
하루 거래량:
343.19K
Relative Volume:
0.56
시가총액:
$208.59M
수익:
-
순이익/손실:
$-31.64M
주가수익비율:
-4.5906
EPS:
-0.4226
순현금흐름:
$-13.98M
1주 성능:
-5.37%
1개월 성능:
-6.73%
6개월 성능:
-50.38%
1년 성능:
+0.00%
1일 변동 폭
$1.915
$2.01
1주일 범위
$1.91
$2.10
52주 변동 폭
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.94 | 208.59M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | H.C. Wainwright | Buy |
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen Pharma Corp. (NASDAQ: NGEN) Share Price, NGEN Stock News, NGEN Share Price & Updates - kalkine.ca
NervGen Pharma Corp. (NGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NervGen Pharma (NGEN) Plans Financial Statement Restatements Ami - GuruFocus
NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results - TipRanks
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments - marketscreener.com
Nervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors - TipRanks
NervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation - TipRanks
NervGen Pharma Corp.(NasdaqCM: NGEN) added to S&P Global BMI Index - marketscreener.com
NervGen Pharma (NASDAQ:NGEN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What's Going On With NervGen Pharma Corp Stock Thursday? - Wealth Awesome
NervGen to Host Inaugural R&D Day on September 30, 2026 - marketscreener.com
Four experts join a live spinal cord research webcast - Stock Titan
NervGen Pharma (NGEN) Edges Higher to $2.33 as Shares Hold Between Key Support and ResistanceVolatility Term Structure - careplusvn.com
Can NervGen Pharma (TSXV:NGEN) Advance Canada’s Biotech Story? - Kalkine Media
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Barchart.com
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 - TMX Newsfile
NervGen Pharma Receives Investment from Drug Manufacturing Partner - TMX Newsfile
NervGen (NGEN) Results Check: The Available Figures Are Largely in Line in the Latest Session; Post-Earnings: Shares Rise 4.30% at the CloseAnnual Report - dars.gov.et
What Makes NervGen Pharma (TSXV:NGEN) A Biotech Watchlist Name? - Kalkine Media
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - vinanet.vn
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, F - GuruFocus
NervGen Pharma (HAM:9UA) Cyclically Adjusted PS Ratio : (As of Aug. 16, 2026) - GuruFocus
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportAndrews Pitchfork - dars.gov.et
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Q2 FY26 net loss widens to C$29.2 million - Bitget
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NervGen Pharma (NGEN) Q3 2025 Earnings: Narrower-than-Expected Loss as Pipeline Development ContinuesFinancial Summary - careplusvn.com
NervGen Pharma (NGEN) Edges Higher to $1.62, Holding Above Key Support LevelBackspread Trade - vinanet.vn
NGEN Q3 2025 Earnings: Narrower Net Loss Brings a 0.99 Percent Positive SurpriseEarnings Trend Analysis - careplusvn.com
NervGen Pharma (NGEN) Holds Near Support as Price Pullback Tests Key LevelsDemand Zone - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NGEN Q3 2025 Earnings: Narrower Loss Surprises as Clinical Pipeline Progress ContinuesPre-Earnings Setup - careplusvn.com
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Corp (NGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):